Medicare Enrolled
Dr. Elizabeth Odumakinde, M.D.
Hematology & Oncology · Concord, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Odumakinde from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Odumakinde?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Odumakinde
Dr. Elizabeth Odumakinde is a hematology & oncology specialist in Concord, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Odumakinde performed 19,745 Medicare services across 1,091 unique beneficiaries.
Between the years covered by Open Payments, Dr. Odumakinde received a total of $14,118 from 73 pharmaceutical and/or device companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Odumakinde is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 24% volume in CA
$14,118 industry payments
Medicare Practice Summary
Medicare Utilization ↗19,745
Medicare services
Top 24% in CA for hematology & oncology
1,091
Unique beneficiaries
$22
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,039 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
6,842 | $6 | $25 |
| Denosumab injection (Prolia/Xgeva) | 5,760 | $18 | $54 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,812 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,550 | $1 | $99 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
828 | $161 | $406 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
393 | $15 | $79 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
356 | $13 | $75 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
339 | $100 | $305 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
281 | $135 | $514 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
278 | $29 | $113 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
205 | $72 | $222 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
170 | $7 | $518 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
168 | $1 | $4 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
116 | $25 | $90 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
98 | $63 | $244 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
82 | $29 | $111 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
81 | $13 | $64 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
65 | $2 | $9 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
61 | $153 | $585 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
59 | $19 | $80 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
46 | $20 | $65 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
42 | $105 | $347 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
37 | $33 | $197 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
31 | $38 | $190 |
| New patient office visit, complex (60-74 min) | 23 | $194 | $569 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
22 | $8 | $15 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.4% high complexity
86.9% medium
8.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,118
Total received (2018-2024)
Avg $2,017/year across 7 years
Top 27% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
73
Companies
707
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,310 (94.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$808 (5.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,646
2023
$3,314
2022
$1,318
2021
$284
2020
$630
2019
$3,929
2018
$2,997
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$181
Novartis Pharmaceuticals Corporation
$167
ABBVIE INC.
$143
Merck Sharp & Dohme LLC
$112
Incyte Corporation
$111
Lilly USA, LLC
$88
JAZZ PHARMACEUTICALS INC.
$79
SERVIER PHARMACEUTICALS LLC
$68
Deciphera Pharmaceuticals Inc.
$57
Janssen Biotech, Inc.
$52
E.R. Squibb & Sons, L.L.C.
$46
BeiGene USA, Inc.
$45
Stemline Therapeutics Inc.
$37
Gilead Sciences, Inc.
$37
SpringWorks Therapeutics, Inc.
$36
Exelixis Inc.
$34
GENZYME CORPORATION
$33
GlaxoSmithKline, LLC.
$32
Agios Pharmaceuticals, Inc.
$32
Bayer Healthcare Pharmaceuticals Inc.
$32
Celgene Corporation
$31
Regeneron Healthcare Solutions, Inc.
$30
Astellas Pharma US Inc
$27
Kyowa Kirin, Inc.
$26
ADC Therapeutics America, Inc.
$25
ARRAY BIOPHARMA INC
$25
Ipsen Biopharmaceuticals, Inc
$23
Janssen Pharmaceuticals, Inc
$21
AstraZeneca Pharmaceuticals LP
$18
Top 3 companies account for 29.8% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$1,573
Novartis Pharmaceuticals Corporation
$1,358
E.R. Squibb & Sons, L.L.C.
$999
Merck Sharp & Dohme Corporation
$868
Celgene Corporation
$539
Amgen Inc.
$533
Takeda Pharmaceuticals U.S.A., Inc.
$456
Astellas Pharma US Inc
$427
GENZYME CORPORATION
$398
Merck Sharp & Dohme LLC
$364
Pharmacyclics LLC, An AbbVie Company
$324
Exelixis Inc.
$320
Janssen Biotech, Inc.
$319
Seattle Genetics, Inc.
$311
GlaxoSmithKline, LLC.
$309
Lilly USA, LLC
$274
Genentech USA, Inc.
$246
ABBVIE INC.
$242
AstraZeneca Pharmaceuticals LP
$237
Incyte Corporation
$231
Clovis Oncology, Inc.
$227
Gilead Sciences, Inc.
$226
Kite Pharma, Inc.
$203
SANOFI-AVENTIS U.S. LLC
$200
Seagen Inc.
$172
Daiichi Sankyo Inc.
$167
Janssen Pharmaceuticals, Inc
$164
Regeneron Healthcare Solutions, Inc.
$153
TESARO, Inc.
$126
SERVIER PHARMACEUTICALS LLC
$114
Agios Pharmaceuticals, Inc.
$106
Kyowa Kirin, Inc.
$94
Stemline Therapeutics Inc.
$90
Mirati Therapeutics, Inc.
$88
TerSera Therapeutics LLC
$88
ADC Therapeutics America, Inc.
$87
Octapharma USA, Inc.
$79
JAZZ PHARMACEUTICALS INC.
$79
Deciphera Pharmaceuticals Inc.
$76
Dendreon Pharmaceuticals LLC
$72
Alexion Pharmaceuticals, Inc.
$71
Taiho Oncology, Inc.
$70
BeiGene USA, Inc.
$67
Boehringer Ingelheim Pharmaceuticals, Inc.
$63
EISAI INC.
$60
Teva Pharmaceuticals USA, Inc.
$55
Ipsen Biopharmaceuticals, Inc
$48
EMD Serono, Inc.
$45
Pharmacyclics LLC, an AbbVie Company
$45
R-Pharm US LLC
$43
AbbVie, Inc.
$43
Acrotech Biopharma LLC
$40
Eisai Inc.
$37
SpringWorks Therapeutics, Inc.
$36
Sirtex Medical Inc
$32
Bayer Healthcare Pharmaceuticals Inc.
$32
Blueprint Medicines Corporation
$31
Karyopharm Therapeutics Inc.
$29
Organon LLC
$28
Jazz Pharmaceuticals Inc.
$28
ARRAY BIOPHARMA INC
$25
Otsuka America Pharmaceutical, Inc.
$24
TAIHO ONCOLOGY, INC.
$24
Genmab U.S., Inc.
$24
AVEO Pharmaceuticals, Inc.
$23
Emmaus Medical, Inc.
$22
GE HealthCare
$22
SOBI, INC
$22
INSYS Therapeutics Inc
$21
Shire North American Group Inc
$19
Adaptive Biotechnologies Corporation
$18
Helsinn Therapeutics (U.S.), Inc.
$16
Lexicon Pharmaceuticals, Inc.
$13
Top 3 companies account for 27.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · AYVAKIT · Abraxane · Alecensa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BOSULIF · BRUKINSA · Balversa · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Cabometyx · DIFICID · DOPTELET · ELIQUIS · ELITEK · EMPLICITI · EPKINLY · ERLEADA · Endari · Enhertu · Epkinly · Erleada · FOTIVDA · Fabhalta · GILOTRIF · Halaven · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · NINLARO · NOXAFIL · Neulasta · Nplate · Nubeqa · OGSIVEO · ONCASPAR · ONTRUZANT · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PANZYGA · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · RYDAPT · Repatha · Revlimid · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tibsovo · Truxima · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Voranigo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
86
Per 100K population
7.4
County median income
$125,727
Nearest hospital
JOHN MUIR MEDICAL CENTER - CONCORD CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Odumakinde is a mixed practice specialist, with above-average Medicare volume (top 24% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Odumakinde experienced with epoetin alfa injection (retacrit) for anemia?
Based on Medicare claims data, Dr. Odumakinde performed 6,842 epoetin alfa injection (retacrit) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Odumakinde receive payments from pharmaceutical companies?
Yes. Dr. Odumakinde received a total of $14,118 from 73 companies across 707 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Odumakinde's costs compare to other hematology & oncology specialists in Concord?
Dr. Odumakinde's average Medicare payment per service is $22. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Odumakinde) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Concord
Browse hematology & oncology specialists in Concord ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology